Seamfix Launches Bioregistra to Transform Data Management

Logo

Seamfix Launches Bioregistra to Transform Data Management

PR Newswire

LAGOS, Nigeria, October 18, 2017 /PRNewswire/ —

SEAMFIX, Nigeria’s leading provider of identity management solutions, today launched BioRegistra, an innovative data capture and data management platform. 

     (Photo: http://mma.prnewswire.com/media/586080/Seamfix_launch_BioRegistra.jpg )

BioRegistra is a state of the art platform developed for individuals, corporates and government, among others to assist them capture data, store the data, and have access to the data at any time as they may desire. 

The platform allows a fully automated process that guarantees seamless execution of all KYC business processes, thus enabling faster customer on-boarding and increasing customer satisfaction.

Speaking during the launch, Chimezie Emewulu, Managing Director of SEAMFIX said BioRegistra was conceptualized to deal with the challenge of accurate data management. 

According to him “Our major challenge in Nigeria is gathering needed data for accurate needs and assessment. With BioRegistra, this challenge is history. The platform can be used to capture all forms of data – animate or inanimate”.

Emewulu stated that BioRegistra comes with several benefits which enhance operational excellence. 

“BioRegistra offers several benefits to the user. It prevents fraudulent data capture. The Intelligent quarantine engine is designed to detect fraudulent and fictitious records and prevent them from being processed. In terms of security, the captured data is hosted on a world class, secure, reliable and trusted cloud service so you have no reason to worry about information safety”, he explained. 

The platform also provides data validation and all-time accessibility from any part of the world.

He further called on government and companies to start making data driven decisions for improved efficiency. 

“We want government and companies to start making data-driven decisions and this cannot happen if data is still locked in files and paper archives. Traditionally in Nigeria, we fill paper-based forms in loads of situations when we are applying for different things from our letter of identification at the local government areas to affidavits at courts to even marriage registry. BioRegistra eliminates this stress because it enables capture of data into a central database with real time analysis. It is better, more efficient and cost effective when decisions are made based on data which is quickly available”, he added.

Commenting on the platform, Chibuzor Onwurah, Executive Director, SEAMFIX said that BioRegistra reflects the spirit of today’s business environment which is anchored data. 

According to him, “In today’s business climate, insightful data is king. Informed decisions are made based on data. BioRegistra is designed to deliver this insightful data in the hands of discerning individuals, corporate organisations and governments in real time.” 

He added that the unique features of BioRegistra are a demonstration of the customer-centric approach adopted by the company to ensure that users derive maximum value from the platform.

The launch event was attended by several dignitaries from the private and public sectors.

About Seamfix 

Seamfix, the leading identity management solutions provider in Nigeria established in 2007 when some young and talented individuals teamed up to make a remarkable change in the society using technology. Seamfix specializes in providing technology-enabled platforms that will serve as a driving force for people and businesses to achieve more daily. Over the years, Seamfix has built systems with footprints in Identity management, Digitization, and Enterprise Business Solutions.

For more information on Seamfix please visit: www.seamfix.com

SOURCE Seamfix

Momenta Pharmaceuticals Announces Date of Third Quarter 2017 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2017 before the U.S. financial markets open on Wednesday, November 1, 2017.   

Management will host a conference call on that date at 10:00 a.m. EDT to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 6492819. A live webcast of the call will be available on the “Investors” section of the company’s website, www.momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call. 

About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Contact:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com

Primary Logo

FDA Advisory Committee Scheduled to Review TLANDO™ on January 10, 2018

SALT LAKE CITY, Oct. 18, 2017 (GLOBE NEWSWIRE) — Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) has scheduled the Bone, Reproductive and Urologic Drugs Advisory Committee (“BRUDAC”) meeting on January 10, 2018 to discuss the New Drug Application (“NDA”) for TLANDO, the Company’s oral testosterone product candidate for the proposed indication of testosterone replacement therapy (“TRT”) in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism.  The FDA has previously set February 8, 2018 as the Prescription Drug User Fee Act (“PDUFA”) goal date.

BRUDAC reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in the practice of obstetrics, gynecology and related specialties, and makes appropriate recommendations to the Commissioner of the FDA.  Although the FDA will consider the recommendation of the panel, the final decision regarding the approval of the product is made by the FDA solely, and the recommendations by the panel are non-binding.

Lipocine announced on August 14, 2017 that the FDA had acknowledged receipt of the NDA resubmission for TLANDO.  The NDA included the results of a Dosing Validation (“DV”) study which confirmed the efficacy of TLANDO with a fixed dose regimen without need for dose adjustment, together with an integrated safety set (“ISS”) from all conducted clinical trials of TLANDO.

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men’s and women’s health using its proprietary drug delivery technologies. Lipocine’s clinical development pipeline includes three development programs TLANDO, LPCN 1111 and LPCN 1107.  TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. TLANDO was well tolerated and met the primary efficacy end-points in Phase 3 testing with twice daily dosing and is currently under FDA review.  LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing.  LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com.

Forward-Looking Statements

This release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding Lipocine’s product candidates and related clinical trials and the FDA review process relating to its product candidates, the expected timing of the FDA review process related to our resubmitted NDA, the path to approvability by the FDA of Lipocine’s development programs, the potential uses and benefits of our product candidates, and our product development efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that the FDA will not approve any of our products, the risk that BRUDAC may make a negative recommendation to the Commissioner of the FDA with respect to TLANDO, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including that the FDA will determine there are deficiencies in our resubmitted NDA, the receipt of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law. 

CONTACT:

Morgan Brown
Executive Vice President & Chief Financial Officer
Phone: (801) 994-7383
mb@lipocine.com

Investors:
Hans Vitzhum
Phone: (646) 597-6979
hans@lifesciadvisors.com

Primary Logo